NewsRelease

JournalArticle Cites HemoVoid™ and AlbuVoid™ Enrichment for LC-MSProteomic Analysis of Osteogenic and Fibrogenic Blood Composites

MONMOUTHJUNCTION, NJ, April15,2021 -- Biotech Support Group reports on a recent research articledescribing the simplicity and efficiency of two depletiontechnologies – one for Albumin and one Hemoglobin, to quantifyproteome abundance changes upon biphasic calcium phosphate (BCP)ceramics embedded in blood clots. 

Thecitation is:

Jing,Lun, et al. "PROTEOMICANALYSIS IDENTIFIED LBP AND CD14 AS KEY PROTEINS IN BLOOD/BIPHASICCALCIUM PHOSPHATE MICROPARTICLE INTERACTIONS." ActaBiomaterialia (2021).

Immediately upon implantation, scaffolds for bone repair areexposed to the patient’s blood. Biphasic calcium phosphate (BCP)ceramics are considered as the gold standard in bone reconstructionsurgery. Here, in a LC-MS/MS proteomic study, the authors comparedthe differentially expressed blood proteins (plasma and blood cellproteins) and the deregulated signaling pathways of osteogenic andfibrogenic blood composites. The article describes use of HemoVoid™ for depletion of Hemoglobinprior to LC-MS analysis, “eachcomposite material or 4 blood clots were pooled into 3ml of cooledlysis buffer [HEPES 50mM (pH 7.4); NaCl 150mM; EDTA 20mM (pH 8);CHAPS 1%; DTT 1mM; Protease and Phosphatase inhibitor cocktail]. Theywere let on ice for 30min with regular vortexings and centrifuged at4°C, 8000g, 15 min. The supernatants were collected, and hemoglobindepleted using several HemoVoid™ columns (Biotech Support Group).Whenindicated, albumin was also partially removed using AlbuVoid™depletion reagent kit (Biotech Support Group) following themanufacturer’s instructions.” From these enrichment steps, theinvestigators found respectively 80 and 92 proteins differentiallyexpressed between blood clot and BCP 80-200 or BCP 200-500 bloodcomposites. After albumin depletion, analysis of the significantderegulated proteins showed that 27 signaling pathways significantlychanged in blood cells stimulated with BCP 80-200 particles comparedto blood cells in blood clot, whereas only 6 of these pathways weresignificantly deregulated with BCP 200-500 particles. These dataobtained after low abundance protein enrichment confirmed that theacute phase response protein, as well as LXR and.FXRpathways, were highly modulated in BCP blood composites but,conversely to what was observed without albumin depletion, these 3pathways were more strongly altered by the BCP 80- 200 particles.Understanding the molecular events following the interactions of thepatient’s blood with biomaterials is crucial in the development ofbone substitutes at least as effective as bone grafting. Theauthors concludethat blood/BCP-induced osteogenesis is associated with a higherexpression of fibrinogen (FGN) and an upregulation of the Myd88- andNF-κB-dependent TLR4 signaling cascade. They also highlighted thekey role of the LBP/CD14 proteins in the TLR4 activation of bloodcells by BCP particles. 

“Here is an excellent report demonstrating a very important advantage of the variety of sample prep products that we supply. First, the article shows the productivity of HemoVoid™ - a negative selection strategy, whereby Hemoglobin very selectively passes through the beads without binding. Also, this article justifies looking at alternative sample prep strategies, as their observational biases can be valuable. Here we see after AlbuVoid™, a different set of regulated proteins and pathways between the sample types. This is mostly a different set of proteins and pathways then what was observed without albumin depletion, demonstrating the value of sub-proteome enrichment.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Formore information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

Formore information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

Formore information on AlbuVoid™, visit:

https://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

Formore information on all of our Albumin & IgG removal products,visit:

https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, and HemogloBind™ and HemoVoid™ for hemoglobinremoval. From these innovations, the company has acquiredknowledgebase and biomarker intellectual property assets that supportdiscoveries of protein markers from blood, with special emphasis onearly detection and personalized medical decisions for cancerpatients. For more information, gotohttp://www.biotechsupportgroup.com

ForBusiness Development, Contact:
MatthewKuruc 732-274-2866, [email protected]